Search clinical trials for: Engerix-B

Total 7079 results

GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
Shaare Zedek Medical Center

Terminated

Response to Hepatitis B Vaccine in Celiac Disease Patients

Celiac Disease

Israel
VBI Vaccines Inc.

Completed

Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®

Hepatitis B

Russian Federation
GlaxoSmithKline

Completed

Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y

Hepatitis B
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

Hepatitis B
GlaxoSmithKline

Completed

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region

Malaria

Mozambique
Shaare Zedek Medical Center

Unknown

Comparison of Engerix B Vaccine Versus Sci-B-Vac Vaccine in Celiac Patients

Celiac Disease

Israel
Tel-Aviv Sourasky Medical Center

Unknown

Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease Patients

Hepatitis B | Chronic Kidney Disease

Israel
Emergent BioSolutions

Terminated

Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

Healthy Volunteers

United States
GlaxoSmithKline

Completed

Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years

Hepatitis B

Spain, Czech Republic, Malaysia
GlaxoSmithKline

Completed

Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine

Hepatitis B

Germany, Belgium
GlaxoSmithKline

Completed

Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.

Hepatitis B

Thailand
Hui Zhuang
Guangxi Center for Disease Control and Prevention

Completed

Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students

Immune Response | Hepatitis B | Seroprevalence

China
University of Surrey

Completed

A Study to Characterise Immune Responses Following Immunisations With "Fendrix" or "Engerix B" Hepatitis B Vaccines

Hepatitis B

United Kingdom
GlaxoSmithKline

Completed

Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine

Hepatitis B

Australia, Belgium
Pontificia Universidad Catolica de Chile

Not yet recruiting

Hepatitis B en Haitian Immigrants in Chile: Molecular Characterization and Determination of Vaccine Response

Hepatitis B
GlaxoSmithKline

Completed

Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine.

Hepatitis B

Thailand
Dynavax Technologies Corporation

Completed

Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease

Chronic Kidney Disease

United States
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Hepatitis B

Belgium
University of Oxford

Completed

Observational Study of Immune Response to Hepatitis B Childhood Booster

Healthy

United Kingdom
Dynavax Technologies Corporation

Completed

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease

United States
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Healthy

United States
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

End Stage Renal Disease

Germany
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute

Not yet recruiting

A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection (HBV003)

Chronic Hepatitis b

Australia
GlaxoSmithKline

Completed

LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With/Without HBIg in Newborns to HBeAg+ Mothers

Hepatitis B

Thailand
Dynavax Technologies Corporation

Completed

Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine

Healthy

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Hepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type b

South Africa
Dynavax Technologies Corporation

Completed

Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine

Hepatitis B

Germany, Canada
Merck Sharp & Dohme LLC

Completed

A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)

Hepatitis B
GlaxoSmithKline

Completed

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

Hepatitis B | Hepatitis A

Germany, Belgium, Czechia
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Assess the Anamnestic Immune Response in Healthy 4 to 7 Year-old Children After a Primary Vaccination Series With Either HEXAVAC® or INFANRIX®-HEXA

Hepatitis B

Italy
VBI Vaccines Inc.

Completed

A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults

Hepatitis B

Vietnam
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

Hepatitis B

Germany
GlaxoSmithKline

Completed

Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control

Hepatitis B
GlaxoSmithKline

Completed

Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants

Malaria | Malaria Vaccines

Tanzania
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
Sanofi Pasteur, a Sanofi Company
Merck Sharp & Dohme LLC

Completed

Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®

Hepatitis B | Pertussis | Tetanus | Diphtheria | Polio

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

Hepatitis B
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

Hepatitis B

Austria
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Immunologic Memory (Supp. of ATN 024)

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)

Hepatitis B
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Infections, Papillomavirus

Finland
GlaxoSmithKline

Completed

Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults

Hepatitis B

Austria, Belgium, Denmark, Iceland
Baylor College of Medicine
Centers for Disease Control and Prevention

Unknown

Adolescents' Response to Hepatitis B Vaccine Booster Dose (REACH)

Hepatitis B

United States
Immutep S.A.S.
SGS Aster-Cephac (CRO)

Completed

A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321

Healthy

France
GlaxoSmithKline

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

Hepatitis B

Austria
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule

Hepatitis B | Pertussis | Diphtheria | Polio

Turkey

3

Subscribe